Univmed s.r.o.
- Address
- lock Available on a paid plan
Univmed s.r.o. - Cardiovascular Disease Research Center
Univmed s.r.o. is a specialized medical research facility dedicated to advancing cardiovascular disease prevention and treatment. The center focuses on innovative therapeutic approaches targeting lipid disorders and their role in major cardiovascular events, particularly investigating novel mechanisms for reducing cardiovascular risk in high-risk patient populations.
- Lipoprotein(a) lowering therapies and cardiovascular outcomes research
- Major adverse cardiovascular events (MACE) prevention studies
- Advanced lipid-modifying interventions in established cardiovascular disease
The center participates in multicenter clinical trials evaluating cutting-edge treatments such as pelacarsen, an antisense oligonucleotide targeting elevated lipoprotein(a) levels. Their research expertise encompasses comprehensive assessment of cardiovascular endpoints including cardiovascular death, myocardial infarction, stroke, and urgent coronary revascularization, contributing to the development of precision medicine approaches for patients with established cardiovascular disease and elevated Lp(a) levels.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Novartis Pharma AG1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Univmed s.r.o.
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Pelacarsen (TQJ230) in Reducing Major Cardiovascular Events in Patients with Established Cardiovascular Disease: A Randomized, Double-Blind, Placebo-Controlled Trial | Novartis Pharma AG | Phase III | Not Recruiting | Mar 2020 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pelacarsen | 2 | Unknown | 2020-03-06 | 2026-05-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.